Sara Tolaney· @stolaney1 · X·· 2 days agoScore90
Body · original
TALENT trial presented by Sara Hurvitz: Preop TDXd in HR+ HER2-low breast cancer
Preop TDXd: 7%
TDXd+AI: 3%
TDXd-->TC: 9%
Adding endocrine therapy and sequencing chemo with TDXd didn't seem to improve pCR
@OncoAlert #ESMO2026
1008 views · 21 likes · 17 reposts · 0 replies
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.orgSource: Sara Tolaney · x.com